Theme news

SHERIDAN, WYOMING – May 9, 2025 – Enovis Corporation (NYSE: ENOV), a global leader in medical technology, has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who will also join the Enovis Board of Directors following the Company’s 2025 Annual Meeting of Stockholders, succeeds Matt Trerotola, who has announced his retirement. This strategic leadership transition positions Enovis for continued growth and innovation in the medical technology sector.

SHERIDAN, WYOMING – May 8, 2025 – Invacare is proud to announce the launch of its global fundraiser, Move For Mobility 2025, which aims to provide life-changing wheelchairs to individuals in need around the world. The initiative brings together Invacare employees, ambassadors, clients, and partners in a worldwide effort to raise awareness and funds for the Free Wheelchair Mission, an organization committed to delivering wheelchairs at no cost to people with disabilities in remote communities.

A Strong Partnership with Free Wheelchair Mission

Since its inception, Invacare has partnered with Free Wheelchair Mission, a humanitarian non-profit organization, to help deliver mobility solutions to underserved populations globally. This year marks the sixth year of this partnership, with Invacare contributing its engineering, testing, and distribution expertise to help create durable and effective wheelchairs.

SHERIDAN, WYOMING – May 8, 2025 – SEALPAC is set to spotlight its new A6max traysealer at IFFA 2025, presenting a game-changing innovation in automated packaging under its #SealingTheFuture campaign. Designed to meet evolving industry demands around sustainability, efficiency, and product diversity, the A6max highlights the universal versatility of SEALPAC’s Amax-series and marks a strategic leap forward for food producers across traditional and alternative protein segments.

Operational Excellence for a Dynamic Market

The SEALPAC A6max is engineered to deliver maximum process reliability from denesting to sealing, ensuring high-quality output even at elevated production speeds. It’s built to address the operational pressures of modern food manufacturing, offering:

SHERIDAN, WYOMING – May 8, 2025 – SEALPAC has officially introduced its groundbreaking F-series thermoformer at IFFA 2025, positioning the new machine as a transformative innovation in industrial packaging. Purpose-built to redefine thermoforming standards, the F-series integrates intelligent automation, rapid format adaptability, and sustainability-focused engineering—making it a strategic asset for forward-looking food manufacturers and processors.

Rethinking Thermoforming for Modern Industry Needs

Designed entirely from the ground up, the SEALPAC F-series represents a radical departure from traditional thermoformer models. Leveraging decades of German engineering expertise, the F-series has been engineered for maximum operational flexibility, precision processing, and intuitive control.

SHERIDAN, WYOMING – May 8, 2025 – In a strategic move to combat skilled labor shortages while preserving premium product quality, Austrian retailer Kaufhaus Hubmann has integrated SEALPAC’s semi-automatic M-Flex traysealer into its deli department operations. The initiative not only safeguards the company’s renowned service standards but also represents a significant leap toward operational efficiency and sustainable packaging in food retail.

A Scalable Solution to Industry-Wide Staffing Challenges

Faced with rising difficulties in staffing deli counters—an issue echoed across the retail food sector—Kaufhaus Hubmann sought a solution that could maintain its commitment to freshness and service. The answer came in the form of SEALPAC’s M-Flex traysealer, which now allows the company to deliver freshly cut deli products multiple times a day, regardless of employee availability.

SHERIDAN, WYOMING – May 8, 2025 – Mölnlycke Health Care has reiterated its unwavering support for the Wound Care Collaborative Community (WCCC) initiative, which seeks to develop a standardized pre-clinical testing framework for wound dressings. The collaboration aims to drive improvements in patient care by ensuring more consistent and clinically relevant product evaluations across the wound care industry.

The initiative brings together clinicians, materials management teams, regulators, and industry experts with a shared vision: to refine wound dressing standards that better reflect real-world needs. Mölnlycke Health Care has been a steadfast partner in this project, working with leading players in the wound care sector to enhance product development and improve patient outcomes.

SHERIDAN, WYOMING – May 8, 2025 – The 9th AVF Summit – powered by VertiFarm – will bring the global vertical farming community together in Munich this September, uniting top innovators, researchers, and industry leaders under the theme “Global Food Challenges: Vertical Farming as a Catalyst for Innovation & Climate Action.” As climate volatility and global food insecurity intensify, the event signals a strategic inflection point for Controlled Environment Agriculture (CEA) and vertical farming as scalable, sustainable solutions.

Driving Innovation Amid Climate and Resource Pressures

SHERIDAN, WYOMING – May 8, 2025 – swissQprint showcased a compelling suite of innovations at the Fespa Global Print Expo 2025, with its Generation 5 flatbed printers commanding attention among industry leaders and buyers alike. The Swiss manufacturer demonstrated its continued commitment to productivity, customization, and high-margin application potential across global markets.

Next-Generation Flatbed Solutions Redefine Quality and Speed

At the heart of swissQprint’s presentation was the new Generation 5 flatbed printer line, which has been shipping to customers on all five continents since January. Engineered with a modular architecture, the trio of models—Kudu, Nyala, and Impala—offers enhanced flexibility and application diversity, built on a completely redesigned foundation.

SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care has kicked off fiscal year 2025 with robust financial performance, driven by strong organic revenue growth and significant operational efficiencies. The world’s leading provider of dialysis products and services posted a 5% increase in organic revenue, highlighting continued operational improvements in both its Care Enablement and Care Delivery segments.

Strong Financial Results in Q1 2025

In the first quarter of 2025, Fresenius Medical Care achieved notable revenue growth, with total sales rising 3% year-on-year, and organic growth accounting for a 5% increase. The company’s total revenue for Q1 amounted to EUR 4,881 million. Despite the challenges posed by a severe flu season, which impacted dialysis treatment volumes in the U.S., the company demonstrated resilience through its diversified service offerings and strategic operational improvements.

SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care (FME) celebrates a major milestone as its dialysis center in Sokolov, Czech Republic, marks its 40th anniversary. With a commitment to providing high-quality care, NephroCare, under the FME brand, continues to serve around 100 dialysis patients, offering specialized nephrological services and cutting-edge dialysis treatments.

Pioneering Dialysis Care in the Czech Republic

The Sokolov dialysis center, located in the western Bohemia region, was founded in 1985 and has been at the forefront of chronic kidney disease treatment in the Czech Republic. From the beginning, the center’s innovative approach and dedication to patient well-being have set it apart.

SHERIDAN, WYOMING – May 8, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) today confirmed that all proposals presented at its Annual General Meeting of Shareholders (AGM) 2025 have been approved, strengthening the company’s governance structure and positioning its leadership team to execute on long-term strategic objectives in the health technology sector.

Shareholder backing of key appointments and re-appointments underscores continued investor confidence in Philips’ strategic direction. This includes the re-appointment of seasoned leaders Indra Nooyi and Chua Sock Koong to the Supervisory Board, the addition of global health tech expert Bob White, and the renewed mandate for Marnix van Ginneken as a member of the Board of Management.

Leadership Reinforcement for Strategic Execution

SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.

Robust Financial Growth and Increased Efficiency

In a year marked by rising costs and market volatility, B. Braun’s fiscal year 2024 results showcase the company’s ability to drive growth and improve profitability. The company’s sales surged to 9.1 billion euros, up from 8.8 billion euros the previous year. At constant exchange rates, this represents a notable 6.8% increase, aligning with B. Braun’s long-term growth target of 5-7%.

Key highlights from the 2024 fiscal year include:

SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.

Key Appointments and Re-elections

At the 2025 AGM, shareholders re-elected F. Michael Ball as Chair of the Board of Directors, alongside several other members who stood for re-election. This includes Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel, and Dieter Spälti. These appointments ensure the continued leadership and strategic direction of Alcon for the upcoming term.

SHERIDAN, WYOMING – May 8, 2025 – Alcon, the global leader in eye care, has announced its continued partnership with the Association for Research in Vision and Ophthalmology (ARVO) for the Eye Pitch live event, set to take place at the ARVO 2025 annual meeting in Salt Lake City, Utah, on May 3, 2025. This event will serve as a platform for entrepreneurs and researchers within the ophthalmic community to present groundbreaking ideas aimed at transforming eye care.

The Eye Pitch event allows ARVO members to pitch their innovative drug, device, or research proposals to a distinguished panel from both ARVO and the Alcon Seed Fund. The competition aims to spotlight early- and mid-stage innovations in the ophthalmic field, offering participants the chance to advance to the next phase of investment.

A Platform for Innovation

SHERIDAN, WYOMING – May 8, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced the Elecsys® PRO-C3 test, a groundbreaking diagnostic solution designed to assess liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This innovative test, developed in partnership with Nordic Bioscience, provides healthcare providers with a fast and efficient way to evaluate liver fibrosis, a disease that contributes to one in every 25 deaths globally.

The Elecsys PRO-C3 test leverages Roche’s cobas® analyzers, delivering results in just 18 minutes, offering a swift and reliable diagnostic method. This new technology promises to significantly improve patient outcomes by enabling earlier identification of liver fibrosis, particularly in those affected by MASLD, and guiding timely treatment interventions.

SHERIDAN, WYOMING – May 8, 2025 – Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), used for treating HER2-positive breast cancer. The label update will allow for Phesgo to be administered outside of clinical settings, such as at patients’ homes, under the supervision of a healthcare professional.

This strategic recommendation marks a significant advancement in the delivery of cancer treatments, aligning with patient preferences and improving overall healthcare system efficiency. The move towards at-home administration is expected to reduce the strain on healthcare facilities and is expected to bring substantial cost savings for both patients and healthcare systems.

SHERIDAN, WYOMING – May 8, 2025 – Roche has achieved a significant milestone in oncology diagnostics with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This marks the first FDA recognition for a computational pathology companion diagnostic (CDx) device using artificial intelligence, highlighting Roche's continued leadership in cancer diagnostics and precision medicine.

The innovative VENTANA TROP2 RxDx device leverages AI to enhance diagnostic precision, improving the detection of non-small cell lung cancer (NSCLC) and enabling personalized treatment decisions. By utilizing cutting-edge digital pathology and AI-driven algorithms, Roche is setting a new standard for oncological diagnostics, advancing both the accuracy and speed of patient treatment strategies.

SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced that Marc N. Casper, the company’s chairman, president, and chief executive officer, will be presenting at the highly anticipated BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 11:40 a.m. (ET). The presentation will be available via a live webcast, accessible through the Investors section of Thermo Fisher’s official website.

SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced a significant $2 billion investment over the next four years, aimed at enhancing U.S. innovation and manufacturing across the life sciences sector. This strategic investment underscores Thermo Fisher's continued confidence in America's ability to lead global scientific advancement while further supporting biopharma companies in the development and production of life-saving medicines.

Strengthening U.S. Manufacturing Infrastructure

The bulk of the $2 billion investment, amounting to $1.5 billion, will be allocated toward expanding and upgrading Thermo Fisher’s U.S.-based manufacturing operations. This move not only solidifies the company's already strong presence in the U.S. but also positions it as a key player in maintaining a resilient healthcare supply chain.

SHERIDAN, WYOMING – May 08, 2025 – Agilent Technologies Inc. (NYSE: A) has introduced its highly anticipated Seahorse XF Flex Analyzer, an advanced, high-performance 24-well system designed to propel metabolic analysis in complex 3D tissue and organoid models. This groundbreaking tool, accompanied by dedicated consumables and kits, promises to transform the way researchers study cellular metabolism, providing critical insights into disease mechanisms and therapeutic development.

Enhancing Metabolic Research Capabilities

Metabolism plays a central role in cellular functions, powering energy production and processes like biosynthesis, mitochondrial function, and cell fate decisions. Disruptions in metabolism are linked to numerous diseases, making metabolic analysis a critical area of research. Traditionally, 2D models have been used for this purpose, but they often fail to reflect the complex biological interactions that occur in living organisms.